Procter & Gamble Hygiene and Health Care Limited has established September 1, 2026, as the record date for its 62nd Annual General Meeting (AGM) and the payment of dividends. This determination defines which shareholders are eligible to attend the meeting and receive any declared dividend. The company aims to ensure clarity for investors regarding their entitlements ahead of the corporate gathering scheduled for early September.

The 62nd AGM is scheduled to take place on Tuesday, September 8, 2026. Shareholders holding units on the record date will be entitled to participate in the proceedings. If the Board approves a dividend during the meeting, payments will be disbursed to eligible members by October 6, 2026. These dates were communicated to the exchanges following earlier notices issued in May and July 2026.

Key Dates and Details

The company has outlined specific timelines for the upcoming corporate actions. Investors must hold shares on the record date to qualify for voting rights and dividend distribution.

The announcement was signed by Flavia Machado, Authorized Signatory, on August 7, 2026. The notice references previous communications dated May 28, 2026, and July 10, 2026, indicating an updated schedule for the annual meeting. The company requested that the Bombay Stock Exchange and the National Stock Exchange of India Limited take these details on record.

Shareholder Eligibility

The record date serves as the cutoff point for identifying shareholders who have the right to vote at the AGM. Only those whose names appear in the register of members on September 1, 2026, will be considered eligible. This standard procedure ensures that the list of participants is finalized before the meeting convenes on September 8.

Dividend entitlement is also tied to this same record date. While the exact dividend amount has not been specified in this filing, the company confirmed that if approved by shareholders at the AGM, the funds will be distributed by October 6, 2026. This timeline provides a clear window for the processing and transfer of funds to eligible accounts.

Procter & Gamble Hygiene and Health Care Limited reported a 34% year-on-year decline in net profit for the quarter ended June 30, 2026, citing commodity cost fluctuations driven by geopolitical uncertainties. The Mumbai-based FMCG major posted a net profit of ₹126 crore (₹126.27 crore) for Q1FY26, down from ₹192.06 crore in the corresponding period of FY25. Revenue from operations contracted 5% to ₹891.46 crore, while EBITDA margin compressed sharply to 19.1% from 28.4%, reflecting significant operational pressure amidst strategic investments in innovation and advertising.

The Board of Directors approved the unaudited financial results at a meeting held on July 29, 2026. The results were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34) and reviewed by the Audit Committee. Statutory Auditors Kalyaniwalla & Mistry LLP issued a limited review report, confirming no material misstatement. The figures for the preceding quarter ended March 31, 2026, represent balancing figures between audited full-year data and published year-to-date figures.

Financial Performance Overview

The following table summarizes the key financial metrics for Q1FY26 against the corresponding period last year:

A detailed breakdown of income and expenditure items is presented below:

Expense Analysis and Strategic Investment

Total expenses rose 7.53% to ₹73,126 lakhs, outpacing the revenue decline and compressing margins significantly. Advertising and sales promotion expenses increased by 21% to ₹83.32 lakhs from ₹68.73 lakhs, indicating continued investment in brand visibility despite softer sales. Employee benefits expense grew 12% to ₹54.36 lakhs. Conversely, finance costs saw a reduction to ₹0.27 lakhs from ₹0.07 lakhs, while cost of raw materials consumed increased moderately to ₹200.24 lakhs.

Profit before tax fell 35.92% to ₹16,963 lakhs. Income tax expense was ₹43.36 lakhs, including current tax of ₹43.89 lakhs and a deferred tax credit of ₹0.53 lakhs. Earnings per share (basic and diluted) declined to ₹38.90 from ₹59.17 in the previous year's corresponding quarter.

What the Numbers Show

The sharp contraction in EBITDA margin—from 28.4% to 19.1% year-on-year—underscores the scale of operational challenges facing the company in Q1FY26. Kumar Venkatasubramanian, Managing Director, attributed the PAT impact to commodity cost fluctuations due to geopolitical uncertainties. The divergence between revenue decline and expense growth highlights significant operational leverage pressures. The 21% surge in advertising spend suggests management is prioritizing market share retention or new product penetration over immediate profitability, aligning with the stated strategy to position the company for long-term competitiveness. The absence of segment-wise disclosure, as Health Care and Hygiene products are aggregated into a single reportable segment, limits granular analysis of which product lines drove the volume or price mix changes.